



(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 471/06 (2006.01)
A61K 31/4375 (2006.01)

(21) International Application Number:

PCT/US2022/045621

(22) International Filing Date:

04 October 2022 (04.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/252,534 05 October 2021 (05.10.2021) US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US];
3545 Cray Court, San Diego, CA 92121 (US).

(72) Inventors: **HALLIN, Jill**; c/o Mirati Therapeutics,
Inc., 3545 Cray Court, San Diego, CA 92121 (US).
CHRISTENSEN, James, Gail; c/o Mirati Therapeutics,
Inc., 3545 Cray Court, San Diego, CA 92121 (US). **BOW-**
CUT, Vickie; c/o Mirati Therapeutics, Inc., 3545 Cray

Court, San Diego, CA 92121 (US). **OLSON, Peter**; c/o Mi-
rati Therapeutics, Inc., 3545 Cray Court, San Diego, CA
92121 (US).


(74) Agent: **POLYAKOV, Mark, V.** et al.; Wood, Phillips,
Katz, Clark & Mortimer, 500 West Madison Street, Suite
1130, Chicago, IL 60661 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

(54) Title: COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS

FIGURE 1



(57) Abstract: The present invention relates to combination therapies for treating KRas G12D cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12D inhibitor of Formula (I), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*